Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESP30TB in pulmonary tuberculosis
NCT07073638Phase 2Recruiting
- Sponsor
- Thirty Respiratory Limited
- Start
- Oct 2025
- Primary completion
- Sep 2026
- Modality
- Inhalation Devices, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of RESP301 in pulmonary tuberculosis (TB) (2 arms), sponsored by Thirty Respiratory Limited. Primary endpoints: Treatment Emergent Adverse Events at 28 days and Early Bactericidal Activity at 14 days. Started Oct 2025; status: recruiting.
02
Drugs
RESP301
03
Conditions
pulmonary tuberculosis (TB)
Beyond the preview
Go deeper on NCT07073638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07073638.